ClinicalTrials.gg
CompletedNCT03632993Updated Sep 7, 2023Results posted

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

A Phase 2 interventional study of collagenase clostridium histolyticum (CCH) in Edematous Skin, sponsored by Endo Pharmaceuticals. Completed at 5 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.

Enrollment
11th of 15
64 · median 150
Started
2018
with 4 others
Phase 2
8 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
14 of 15
Endo Pharmaceuticals

Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 11th largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 2, and was the 9th registered.

Cellulite

71 studies on the registry are indexed under Cellulite; 3 are open to participants now.

Browse Cellulite studies →

Open to participants now

None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →

Where they have run

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Microbial Collagenase in Cellulite as a file.
02

Study summary

The study will evaluate the safety and effectiveness of different injection techniques of Collagenase Clostridium Histolyticum (CCH) for the treatment of adult women with mild, moderate or severe Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).

03

Conditions studied

  • Edematous Skin

Browse trials for

Keywords

  • Edematous Fibrosclerotic Panniculopathy
  • Cellulite
  • Collagenase Clostridium Histolyticum
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

No participant will be assigned to treatment until all eligibility criteria have been satisfied. To qualify for the study a participant must:

  1. Be able to provide voluntary written prior to the initiation of any study specific procedures per the policy of the governing Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
  2. Be female and at least 18 years of age at the time of consent.
  3. Have evidence of cellulite in 2 bilateral treatment areas (defined as right and left buttocks or right and left posterolateral thighs) as assessed by the Investigator at the Screening visit, and fulfills the following requirements:

    1. has a score of 2 (mild), 3 (moderate) or 4 (severe) as reported by the Investigator (CR-PCSS) in 2 treatment areas (two thighs or two buttocks) at the Screening Visit.
    2. has at least 2 dimples from each treatment area that:

      • are isolated and separated by at least 5 centimeters (cm) from any other dimples.
      • score 2 or 3 on the Hexsel depression scale.
      • have dimple width: length ratio ≥ 0.5.
  4. Be willing to apply sunscreen to the dosing areas before each exposure to the sun while participating in the study (that is, screening through end of study).
  5. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at screening.
  6. Have a negative serum pregnancy test at the Screening Visit and negative urine pregnancy at Day 1 (before injection of study drug), be using an effective method (for example, abstinence, intrauterine device, hormonal [estrogen/progestin] contraceptives, or double barrier control) for at least 1 menstrual cycle prior to study enrollment and through Day 71; or be menopausal defined as at least 12 months of amenorrhea in the absence of other biological or physiological causes (as determined by the Investigator), or be for at least 1 year, or be surgically sterile (hysterectomy, bilateral oophorectomy, bilateral tubal ligation).
  7. Be willing and able to comply with all protocol required study visits and assessments.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the study:

  1. Is pregnant or is intending to become pregnant during the study.
  2. Is presently nursing/breastfeeding or providing breast milk.
  3. Has any of the following systemic conditions:

    1. Coagulation disorder.
    2. Evidence or history of (other than excised basal-cell carcinoma) unless there has been no recurrence in at least 5 years.
    3. History of keloidal scarring or abnormal wound healing.
    4. Concurrent diseases or conditions that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the participant's well-being.
    5. Evidence of abnormalities on physical examination, vital signs, (ECG), or clinical laboratory values.
  4. Has any of the following local conditions in the areas to be treated:

    1. History of lower extremity thrombosis or post-thrombosis syndrome.
    2. Vascular disorder (for example, varicose veins, telangiectasia).
    3. Inflammation or active infection.
    4. Severe skin laxity, flaccidity, and/or sagging.
    5. Active cutaneous alteration including rash, eczema, psoriasis, or skin cancer.
  5. Has a tattoo located within 2 cm of the site of injection.
  6. Requires anticoagulant or antiplatelet medication during the study or has received anticoagulant or antiplatelet medication (except for ≤ 150 mg aspirin daily) within 7 days before injection of study drug.
  7. Has used any of the following for the treatment of EFP on the area to be treated within the timelines identified below or intends to use any of the following at any time during the course of the study:

    1. Liposuction within the treatment areas during the 12-month period before injection of study drug.
    2. Injections (for example, mesotherapy); radiofrequency device treatments; laser treatment; or surgery (including subcision and/or powered subcision) within the treatment areas during the 12-month period before injection of study drug.
    3. Any treatment for EFP/cellulite on treatment areas during the 12-month period before the injection of study drug.
    4. Endermologie® or similar treatments within the treatment areas during the 6-month period before injection of study drug.
    5. Massage therapy within the treatment areas during the 3-month period before injection of study drug.
    6. Creams (for example, Celluvera™, TriLastin®) to prevent or mitigate EFP within the treatment areas during the 2-week period before injection of study drug.
  8. Has received an investigational drug or treatment within 30 days before injection of study drug.
  9. Has a known systemic allergy to collagenase or any other of study drug.
  10. Has a history of drug or alcohol abuse.
  11. Intends to initiate an intensive sport or exercise program during the study.
  12. Intends to initiate a weight reduction program during the study.
  13. Intends to use tanning spray or tanning booths during the study.
  14. Has previously received any collagenase treatments (for example, Santyl® ointment and/or XIAFLEX/XIAPEX®).
  15. Was a participant in a previous cellulite clinical trial of EN3835: AUX-CC-830, AUX-CC-831, EN3835-102, EN3835-104, EN3835-201, EN3835-202, EN3835-205, EN3835-302, or EN3835-303.
  16. Any other condition(s) that, in the Investigator's opinion, might indicate the participant is unsuitable for the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Treatment I: CCH Shallow Injection, 3 Aliquots

    In Treatment I, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 milliliters (mL) aliquots (for a total injection volume of 0.3 mL). During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area).

    Drug: collagenase clostridium histolyticum (CCH)

  • Active comparator
    Treatment II: CCH Shallow Injection, 1 Aliquot

    In Treatment II, CCH will be injected subcutaneously while the participant is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot. During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area).

    Drug: collagenase clostridium histolyticum (CCH)

  • Active comparator
    Treatment III: CCH Deep Injection, 1 Aliquot

    In Treatment III, CCH will be injected subcutaneously while the participant is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot. During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area).

    Drug: collagenase clostridium histolyticum (CCH)

  • Active comparator
    Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots

    In Treatment IV, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL). During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5 mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area).

    Drug: collagenase clostridium histolyticum (CCH)

  • Active comparator
    Treatment V: CCH Shallow Injections, 4 Aliquots

    In Treatment V, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL). During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2 mL of CCH (4 aliquots of 0.3 mL each). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area).

    Drug: collagenase clostridium histolyticum (CCH)

Interventions

  • Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.

06

What researchers measure

Primary outcomes

  1. Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22

    Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 22 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).

    Time frame: Day 22

  2. Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 43

    Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 43 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).

    Time frame: Day 43

  3. Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 71

    Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 71 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).

    Time frame: Day 71

  4. Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 22

    Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)

    Time frame: Baseline, Day 22

  5. Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 43

    Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)

    Time frame: Baseline, Day 43

  6. Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 71

    Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)

    Time frame: Baseline, Day 71

Secondary outcomes

  1. Change From Baseline of Dimple Volume by Treatment Region

    For each treated buttock and thigh, 4 dimple parameters including the maximum length (largest straight line distance across the dimple), maximum width (largest straight line distance perpendicular to the maximum length measurement), surface are, and volume (between the base of the dimple and an interpolated surface) of the target dimple were assessed. A negative change from Day 1 indicated an improvement. Volume of Dimple from Day 1 pre-marking was analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the measurement for the average of left and right of treatment areas (that is, average of left buttock posterior and right buttock posterior; average of left thigh lateral, left thigh oblique, left thigh posterior, right thigh lateral, right thigh oblique, and right thigh posterior).

    Time frame: Baseline, Day 22, Day 43, and Day 71

07

Results

Posted Sep 7, 2023

Participant flow

Participant flow — Overall Study
MilestoneTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Started7667666776
Completed6567646575
Not completed1100020201
Withdrew: Withdrawal by subject1000000001
Withdrew: Protocol non-compliance0100000000
Withdrew: Lost to follow-up0000010100
Withdrew: Adverse event0000010100

Outcome measures

PrimaryAesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22

Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 22 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).

Time frame:
Day 22
Reported as:
Least squares mean · score on a scale
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22
score on a scaleTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 221.08 (0.51 to 1.65)1.10 (0.46 to 1.74)0.75 (0.18 to 1.32)0.50 (-0.04 to 1.04)0.67 (0.10 to 1.24)0.20 (-0.44 to 0.84)0.83 (0.26 to 1.40)0.67 (0.09 to 1.25)1.00 (0.47 to 1.53)1.10 (0.46 to 1.74)
PrimaryAesthetic Appearance Improvement Likert Scores by Treatment Region at Day 43

Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 43 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).

Time frame:
Day 43
Reported as:
Least squares mean · score on a scale
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 43
score on a scaleTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 430.75 (0.18 to 1.32)1.40 (0.76 to 2.04)1.10 (0.47 to 1.73)0.57 (0.03 to 1.11)1.00 (0.43 to 1.57)-0.01 (-0.64 to 0.64)1.17 (0.60 to 1.74)0.42 (-0.16 to 1.00)1.21 (0.69 to 1.74)0.70 (0.06 to 1.34)
PrimaryAesthetic Appearance Improvement Likert Scores by Treatment Region at Day 71

Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 71 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).

Time frame:
Day 71
Reported as:
Least squares mean · score on a scale
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 71
score on a scaleTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 711.08 (0.51 to 1.65)0.92 (0.34 to 1.50)1.08 (0.51 to 1.65)0.43 (-0.11 to 0.97)1.00 (0.43 to 1.57)0.12 (-0.59 to 0.84)0.50 (-0.07 to 1.07)0.30 (-0.34 to 0.94)1.29 (0.76 to 1.81)0.60 (-0.04 to 1.24)
PrimaryChange From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 22

Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)

Time frame:
Baseline, Day 22
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 22
score on a scaleTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 22-0.83 (-1.28 to -0.39)-0.30 (-0.84 to 0.24)-0.17 (-0.61 to 0.28)-0.43 (-0.89 to 0.03)-0.17 (-0.61 to 0.28)-0.20 (-0.74 to 0.34)-0.83 (-1.28 to -0.39)-0.67 (-1.16 to -0.17)-0.14 (-0.56 to 0.27)-0.20 (-0.74 to 0.34)
PrimaryChange From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 43

Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)

Time frame:
Baseline, Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 43
score on a scaleTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 43-0.92 (-1.36 to -0.47)-0.40 (-0.94 to 0.14)-0.40 (-0.89 to 0.09)-0.43 (-0.89 to 0.03)-0.50 (-0.95 to -0.05)-0.40 (-0.94 to 0.14)-0.83 (-1.28 to -0.39)-0.67 (-1.16 to -0.17)-0.36 (-0.77 to 0.06)-0.60 (-1.14 to -0.06)
PrimaryChange From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 71

Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)

Time frame:
Baseline, Day 71
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 71
score on a scaleTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 71-1.17 (-1.61 to -0.72)-0.33 (-0.83 to 0.16)-0.08 (-0.53 to 0.36)-0.29 (-0.74 to 0.17)-0.67 (-1.11 to -0.22)-0.75 (-1.36 to -0.14)-0.83 (-1.28 to -0.39)-1.40 (-1.94 to -0.86)-0.36 (-0.77 to 0.06)-0.80 (-1.34 to -0.26)
SecondaryChange From Baseline of Dimple Volume by Treatment Region

For each treated buttock and thigh, 4 dimple parameters including the maximum length (largest straight line distance across the dimple), maximum width (largest straight line distance perpendicular to the maximum length measurement), surface are, and volume (between the base of the dimple and an interpolated surface) of the target dimple were assessed. A negative change from Day 1 indicated an improvement. Volume of Dimple from Day 1 pre-marking was analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the measurement for the average of left and right of treatment areas (that is, average of left buttock posterior and right buttock posterior; average of left thigh lateral, left thigh oblique, left thigh posterior, right thigh lateral, right thigh oblique, and right thigh posterior).

Time frame:
Baseline, Day 22, Day 43, and Day 71
Reported as:
Least squares mean · mm^3
Change From Baseline of Dimple Volume by Treatment Region
mm^3Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Day 22-0.01 (-0.04 to 0.01)-0.02 (-0.07 to 0.02)-0.001 (-0.03 to 0.02)-0.04 (-0.08 to -0.0001)-0.01 (-0.04 to 0.01)0.00 (-0.05 to 0.05)-0.01 (-0.04 to 0.01)-0.01 (-0.06 to 0.03)-0.04 (-0.06 to -0.01)-0.04 (-0.09 to 0.01)
Day 43-0.02 (-0.05 to 0.00)-0.03 (-0.08 to 0.02)-0.02 (-0.05 to 0.00)-0.04 (-0.08 to 0.00)-0.01 (-0.04 to 0.01)0.01 (-0.04 to 0.06)-0.01 (-0.04 to 0.01)-0.02 (-0.07 to 0.02)-0.04 (-0.07 to -0.02)-0.06 (-0.11 to -0.01)
Day 71-0.02 (-0.05 to 0.00)-0.02 (-0.07 to 0.02)-0.04 (-0.06 to -0.01)-0.02 (-0.07 to 0.02)-0.01 (-0.04 to 0.02)0.04 (-0.02 to 0.09)-0.02 (-0.05 to 0.01)-0.02 (-0.07 to 0.03)-0.05 (-0.07 to -0.02)-0.05 (-0.09 to 0.00)

Adverse events

Collected over Day 1 (after dosing) through Day 71. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)0/6 (0%)0/6 (0%)6/6 (100%)
Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)0/6 (0%)0/6 (0%)6/6 (100%)
Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)0/6 (0%)0/6 (0%)4/6 (66.7%)
Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)0/7 (0%)0/7 (0%)7/7 (100%)
Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)0/6 (0%)0/6 (0%)6/6 (100%)
Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)0/6 (0%)0/6 (0%)6/6 (100%)
Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)0/6 (0%)0/6 (0%)6/6 (100%)
Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)0/7 (0%)1/7 (14.3%)7/7 (100%)
Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)0/7 (0%)1/7 (14.3%)7/7 (100%)
Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/60/60/60/70/60/60/60/71/70/6
AsthmaRespiratory, thoracic and mediastinal disorders0/60/60/60/70/60/60/60/71/70/6
HospitalizationSurgical and medical procedures0/60/60/60/70/60/60/61/70/70/6
Most frequent other events
Showing 10 of 20
Most frequent other events
EventTreatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)
Injection site painGeneral disorders6/66/63/66/76/66/66/67/76/73/6
Injection site bruisingGeneral disorders5/64/64/67/76/66/63/63/75/76/6
Injection site noduleGeneral disorders3/62/64/66/75/65/60/63/73/75/6
Injection site warmthGeneral disorders2/64/62/63/72/60/61/61/72/72/6
Injection site haemorrhageGeneral disorders1/62/60/60/71/60/63/64/72/70/6
Injection site discolourationGeneral disorders1/61/62/64/71/60/60/60/70/71/6
Injection site pruritusGeneral disorders3/63/61/63/72/60/62/61/72/70/6
Injection site swellingGeneral disorders1/60/60/61/71/60/61/62/71/71/6
Injection site indurationGeneral disorders1/61/60/61/70/60/61/62/70/71/6
Influenza-like illnessGeneral disorders0/60/60/60/71/60/60/60/70/70/6

Baseline characteristics

Safety Population includes all participants who had at least 1 injection of study drug.

Age, Continuous
Age, Continuous(years)Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)Total
Mean50.2 ± 9.8544.7 ± 8.1943.3 ± 10.9545.6 ± 9.5548.7 ± 15.9552.2 ± 13.0451.5 ± 11.9349.0 ± 12.7548.4 ± 10.0039.8 ± 10.2647.3 ± 11.17
Sex: Female, Male
Sex: Female, Male(Participants)Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)Total
Female666766677663
Male00000000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)Total
Hispanic or Latino443631125332
Not Hispanic or Latino223135552331
Unknown or Not Reported00000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)Total
American Indian or Alaska Native00000000000
Asian00000010001
Native Hawaiian or Other Pacific Islander00000000000
Black or African American302101031314
White364665546348
More than one race00000000000
Unknown or Not Reported00000000000
Weight
Weight(kg)Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)Total
Mean90.258 ± 30.243775.660 ± 15.273087.843 ± 23.693384.407 ± 20.215276.687 ± 13.387074.117 ± 13.968265.038 ± 17.008372.396 ± 15.662978.497 ± 12.041396.008 ± 14.979180.012 ± 19.0943
Height
Height(cm)Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)Total
Mean158.7 ± 3.67162.2 ± 3.03161.8 ± 2.14164.4 ± 10.01163.0 ± 6.90162.3 ± 3.88161.5 ± 8.96167.4 ± 10.55164.4 ± 8.96165.2 ± 6.65163.2 ± 7.18
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)Total
Mean35.92 ± 12.64330.30 ± 6.38733.65 ± 9.41531.11 ± 6.27729.13 ± 6.23928.05 ± 4.66924.78 ± 5.20226.40 ± 7.33029.01 ± 4.12335.10 ± 3.92930.27 ± 7.379
Skin Category (Fitzpatrick Scale)
Skin Category (Fitzpatrick Scale)(Participants)Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks)Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs)Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks)Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs)Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks)Treatment III: CCH Deep Injection, 1 Aliquot (Thighs)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks)Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs)Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks)Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs)Total
I (Pale White)00000001001
II (Fair)121021122012
III (Darker White)020023301011
IV (Light Brown)223621103323
V (Brown)00110011037
VI (Dark Brown or Black)30100103109
08

Study locations

5 sites
  • Endo Clinical Trial Site #1
    Coral Gables, Florida 33146, United States
  • Endo Clinical Trial Site #5
    Miami, Florida 33137, United States
  • Endo Clinical Trial Site #2
    New York, New York 10016, United States
  • Endo Clinical Trial Site #4
    New York, New York 10022, United States
  • Endo Clinical Trial Site #3
    New York, New York 10065, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Jan 2019, 4 months.

Results were first posted in Sep 2023, 4 years 7 months after primary completion. A results delay was requested in Jan 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2018
First posted
Aug 16, 2018
StartActual
Sep 18, 2018
Primary completionActual
Jan 24, 2019
CompletionActual
Jan 24, 2019
Results delay requested
Jan 24, 2020
Results first posted
Sep 7, 2023
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03632993
Responsible party
Sponsor
First posted
Aug 16, 2018
Start date
Sep 18, 2018
Primary completion
Jan 24, 2019
Completion
Jan 24, 2019
Results posted
Sep 7, 2023
Last update
Sep 7, 2023

Study contacts

George Omburo
study director · Endo Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion